Represents 7th Consecutive Year of 20% or More Constant Currency Revenue Growth ACTON, Mass.–(BUSINESS WIRE)–Please…
Combined company will be focused on advancing Enliven’s clinical-stage pipeline of precision oncology programs Shares…
– Initiated enrollment in Phase 1B clinical trial of SL-172154 in combination with mirvetuximab soravtansine…
— Company expects to announce data for Factor VIII expression in non-human primates in 2023…
FREMONT, CA, Feb. 23, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ:…
CHATHAM, N.J., Feb. 23, 2023 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix…
Biotherapeutics Application of CodeEvolver® Validated by Recent Data Supporting the Potential for Three Upcoming Investigational…
Advanced RLY-4008: Reported interim data with 88% overall response rate at pivotal dose and 63%…
Initiated ReSPECT-GBM Phase 2 and ReSPECT- LM Phase 1 trials for CNS cancers Awarded $17.6…
Interim Data from Phase 1 Proof-of-Concept Arm Indicates CDX-7108 Improves Lipid Absorption REDWOOD CITY, Calif.,…
– Transformational year ahead with critical Phase 2 readouts expected for programs in hepatitis B,…
LOS ANGELES, Feb. 23, 2023 (GLOBE NEWSWIRE) — (NASDAQ: ENOB) — On February 16, 2023, Enochian…
– Phase 1 data for ziftomenib highlighted by 30% CR rate among 20 patients with…
NEW YORK, Feb. 23, 2023 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. (Nasdaq: SLS)…
Key 2022 and post–period events Dr. Paul Stoffelsi appointed as Chief Executive Officer and Chairman…
Data to be Presented in Five Poster Presentations at the 2023 American Academy of Allergy,…
Recently received U.S. FDA accelerated approval of FILSPARI™ (sparsentan), the first and only non-immunosuppressive therapy…
– Generated Record Quarterly and Full-Year Net Revenue of $129.6 and $463.9 Million – …
Vancouver, British Columbia–(Newsfile Corp. – February 23, 2023) – Solarvest BioEnergy Inc. (TSXV: SVS) (“Solarvest”, or the…
GAAP earnings per share were $2.73 in 2022 compared to $2.63 in 2021 Adjusted earnings…